Michael Conick Hanley
Chief Operating Officer at ALTO NEUROSCIENCE, INC.
Net worth: 50 608 $ as of 2024-05-30
Michael Conick Hanley active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ALTO NEUROSCIENCE, INC. | Chief Operating Officer | 2024-05-19 | - |
Career history of Michael Conick Hanley
Former positions of Michael Conick Hanley
| Companies | Position | Start | End |
|---|---|---|---|
| SPYRE THERAPEUTICS, INC. | Corporate Officer/Principal | 2019-11-03 | 2023-04-13 |
Esteve Pharmaceuticals S.A.
 Esteve Pharmaceuticals S.A. Pharmaceuticals: OtherHealth Technology Esteve Pharmaceuticals S.A. operates as a global pharmaceutical company. It provides Ophthalmology and other Pathologies therapies. The company is headquartered in Barcelona, Spain. | Corporate Officer/Principal | 2018-03-31 | 2019-08-31 |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Sales & Marketing | 2015-06-30 | 2017-05-31 |
Training of Michael Conick Hanley
| Kellogg School of Management | Masters Business Admin |
| Notre Dame University | Undergraduate Degree |
Statistics
International
| United States | 4 |
| Lebanon | 2 |
| Spain | 2 |
Operational
| Corporate Officer/Principal | 2 |
| Masters Business Admin | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| SPYRE THERAPEUTICS, INC. | Health Technology |
| ALTO NEUROSCIENCE, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Esteve Pharmaceuticals S.A.
Esteve Pharmaceuticals S.A. Pharmaceuticals: OtherHealth Technology Esteve Pharmaceuticals S.A. operates as a global pharmaceutical company. It provides Ophthalmology and other Pathologies therapies. The company is headquartered in Barcelona, Spain. | Health Technology |
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
